Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Accumulated Expenses of $1.0 billion for Q1 2026, down 3.9% year-over-year from $1.1 billion in Q1 2025, and down 1.14% quarter-over-quarter from $1.0 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 3.9% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 3.9% YoY), while the FY2025 annual figure was $1.0 billion, up 13.53% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
- The five-year high for Accumulated Expenses was $1.1 billion in Q1 2025, with the low at $593.2 million in Q2 2022.
- The 5-year median for Accumulated Expenses is $803.3 million (2022), against an average of $828.7 million.
- The sharpest annual moves came in 2022 and 2026: Accumulated Expenses jumped 61.67% in 2022, then fell 3.9% in 2026.
- Jazz Pharmaceuticals' Accumulated Expenses stood at $803.3 million in 2022, then dropped by 1.16% to $793.9 million in 2023, then gained by 14.74% to $910.9 million in 2024, then climbed by 13.53% to $1.0 billion in 2025, then declined by 1.14% to $1.0 billion in 2026.
- Business Quant data shows JAZZ's Accumulated Expenses at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 1.02 Bn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.00 Bn |
| Jun 30, 2025 | 874.81 Mn |
| Mar 31, 2025 | 1.06 Bn |
| Dec 31, 2024 | 910.95 Mn |
| Sep 30, 2024 | 858.58 Mn |
| Jun 30, 2024 | 800.99 Mn |
| Mar 31, 2024 | 826.53 Mn |
| Dec 31, 2023 | 793.91 Mn |
| Sep 30, 2023 | 769.94 Mn |
| Jun 30, 2023 | 748.30 Mn |
| Mar 31, 2023 | 712.35 Mn |
| Dec 31, 2022 | 803.26 Mn |
| Sep 30, 2022 | 668.39 Mn |
| Jun 30, 2022 | 593.21 Mn |
| Mar 31, 2022 | 604.71 Mn |
| Dec 31, 2021 | 666.30 Mn |
| Sep 30, 2021 | 603.72 Mn |